Bloomberg News (6/21, Edney) reported Cubist Pharmaceuticals Inc. has received the green signal from the FDA to market its antibiotic Sivextro (tedizolid phosphate) “to treat acute bacterial skin infections, including potentially fatal MRSA.” The article noted that the FDA approved Sivextro “for use in both intravenous and oral forms,” citing an agency statement. The article noted that Sivestro is the second antibiotic “the FDA has approved in a month to treat MRSA.”
The AP (6/23, Perrone) reported that the FDA gave Sivextro “an expedited review under a 2012 law designed to encourage drugmakers to invest in researching and development of new antibiotics.” The law also gives Cubist five more years of “exclusive marketing rights to the drug.”
The Boston Globe (6/20) reported that with the latest approval, Cubist will now have four antibiotics on the market. “The others are its lead drug Cubicin, which also fights Gram-positive infections; Entereg, which speeds gastrointestinal recovery in patients who have had bowel surgery;” and Dificid (fidaxomicin), “a drug treating diarrhea caused by intestinal inflammation.”
No comments:
Post a Comment